The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

And we're really excited to have the Vertex IR team with us ... is a selective NaV1.8 channel inhibitor. So, we're stopping pain where it occurs in the peripheral neurons and because of that we don't ...

Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, presented the latest data from its eIF4E program at the European Society for Medical Oncology ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Insmed (INSM – Research Report), with a price target ...

Changes clinical practice: The risks and benefits of adjuvant aromatase inhibitors (AIs) should be weighed carefully, especially in postmenopausal women with early-stage, hormone-receptor positive ...

Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two ...

The other near-term shot at blockbuster revenues is Vertex's pain therapy, Suzetrigine, a "novel, highly selective Nav1.8 pain signal inhibitor" which Vertex says: has the potential to provide a ...

BigEndian Semiconductors, a fabless-semiconductor design startup, raised $3 million in a funding round led by Vertex Ventures SEA & India. The funds will be used to expand the company’s engineering ...

Citation: PARP1 selective inhibitor yields potent and durable antitumor activity in patient-derived preclinical models (2024, September 3) retrieved 19 September 2024 from https://medicalxpress ...